{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:30:04Z","timestamp":1787157004427,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031935","name":"Xi'an Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570684"],"award-info":[{"award-number":["82570684"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172167"],"award-info":[{"award-number":["82172167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370659"],"award-info":[{"award-number":["82370659"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.metabol.2026.156681","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:33:54Z","timestamp":1782052434000},"page":"156681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["SUMOylation of HMGCS1 triggers its ubiquitin-dependent degradation to alleviate hepatic steatosis"],"prefix":"10.1016","volume":"183","author":[{"given":"Mengzhou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.metabol.2026.156681_bb0005","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature (in eng)","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2026.156681_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms (in eng)","author":"Steinberg","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2026.156681_bb0015","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review (in eng)","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2026.156681_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155999","article-title":"Global burden of metabolic diseases, 1990-2021 (in eng)","volume":"160","author":"Zhang","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2026.156681_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease (in eng)","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"issue":"7","key":"10.1016\/j.metabol.2026.156681_bb0030","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom (in eng)","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2026.156681_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156397","article-title":"Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis (in eng)","volume":"174","author":"Boutari","year":"2026","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2026.156681_bb0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (in eng)","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.metabol.2026.156681_bb0045","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (in eng)","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2026.156681_bb0050","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.4049\/jimmunol.157.10.4277","article-title":"Protection against Fas\/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin (in eng)","volume":"157","author":"Okura","year":"1996","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.metabol.2026.156681_bb0055","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1152\/physrev.00025.2019","article-title":"SUMO: from bench to bedside (in eng)","volume":"100","author":"Chang","year":"2020","journal-title":"Physiol Rev"},{"issue":"11","key":"10.1016\/j.metabol.2026.156681_bb0060","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41580-022-00500-y","article-title":"Signalling mechanisms and cellular functions of SUMO (in eng)","volume":"23","author":"Vertegaal","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156681_bb0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.molcel.2018.07.027","article-title":"SUMO-mediated regulation of nuclear functions and signaling processes (in eng)","volume":"71","author":"Zhao","year":"2018","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.metabol.2026.156681_bb0070","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1021\/pr500997p","article-title":"Regulation of SUMO2 target proteins by the proteasome in human cells exposed to replication stress (in eng)","volume":"14","author":"Bursomanno","year":"2015","journal-title":"J Proteome Res"},{"issue":"2","key":"10.1016\/j.metabol.2026.156681_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tibs.2020.09.002","article-title":"A chain of events: regulating target proteins by SUMO polymers (in eng)","volume":"46","author":"Jansen","year":"2021","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.metabol.2026.156681_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116898","article-title":"The role and mechanism of SUMO modification in liver disease (in eng)","volume":"177","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2026.156681_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1434338","article-title":"Tissue adaptation to metabolic stress: insights from SUMOylation (in eng)","volume":"15","author":"Xie","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.metabol.2026.156681_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/biom10081154","article-title":"Not so slim anymore-evidence for the role of SUMO in the regulation of lipid metabolism (in eng)","volume":"10","author":"Sapir","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.metabol.2026.156681_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cca.2020.07.044","article-title":"Sumoylation in liver disease (in eng)","volume":"510","author":"Zeng","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.metabol.2026.156681_bb0100","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/MCB.01166-13","article-title":"PIASy-mediated sumoylation of SREBP1c regulates hepatic lipid metabolism upon fasting signaling (in eng)","volume":"34","author":"Lee","year":"2014","journal-title":"Mol Cell Biol"},{"issue":"22","key":"10.1016\/j.metabol.2026.156681_bb0105","doi-asserted-by":"crossref","first-page":"15224","DOI":"10.1074\/jbc.M800910200","article-title":"Growth factor-induced phosphorylation of sterol regulatory element-binding proteins inhibits sumoylation, thereby stimulating the expression of their target genes, low density lipoprotein uptake, and lipid synthesis (in eng)","volume":"283","author":"Arito","year":"2008","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.metabol.2026.156681_bb0110","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255981","article-title":"Fasting-sensitive SUMO-switch on Prox1 controls hepatic cholesterol metabolism (in eng)","volume":"24","author":"Alfaro","year":"2023","journal-title":"EMBO Rep"},{"issue":"2","key":"10.1016\/j.metabol.2026.156681_bb0115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.15252\/embj.201489527","article-title":"A dysregulated acetyl\/SUMO switch of FXR promotes hepatic inflammation in obesity (in eng)","volume":"34","author":"Kim","year":"2015","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.metabol.2026.156681_bb0120","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","article-title":"An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease (in eng)","volume":"29","author":"Kendall","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.metabol.2026.156681_bb0125","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCRESAHA.115.308268","article-title":"UBC9-mediated sumoylation favorably impacts cardiac function in compromised hearts (in eng)","volume":"118","author":"Gupta","year":"2016","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.metabol.2026.156681_bb0130","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1038\/s41467-024-52569-y","article-title":"SUMOylation of warts kinase promotes neural stem cell reactivation (in eng)","volume":"15","author":"Gao","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.metabol.2026.156681_bb0135","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCRESAHA.115.304760","article-title":"Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes (in eng)","volume":"115","author":"Gupta","year":"2014","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.metabol.2026.156681_bb0140","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00125-017-4523-9","article-title":"Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function (in eng)","volume":"61","author":"He","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.metabol.2026.156681_bb0145","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","article-title":"Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer (in eng)","volume":"64","author":"Langston","year":"2021","journal-title":"J Med Chem"},{"issue":"611","key":"10.1016\/j.metabol.2026.156681_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7791","article-title":"A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models (in eng)","volume":"13","author":"Lightcap","year":"2021","journal-title":"Sci Transl Med"},{"issue":"18","key":"10.1016\/j.metabol.2026.156681_bb0155","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood.2021014267","article-title":"The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation (in eng)","volume":"139","author":"Nakamura","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.metabol.2026.156681_bb0160","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clml.2025.04.020","article-title":"Phase I\/II study of subasumstat (TAK-981) in combination with rituximab in relapsed\/refractory non-Hodgkin lymphoma (in eng)","volume":"25","author":"Assouline","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.metabol.2026.156681_bb0165","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.7150\/ijbs.84994","article-title":"The potential role and mechanism of circRNA\/miRNA axis in cholesterol synthesis (in eng)","volume":"19","author":"Chen","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"38","key":"10.1016\/j.metabol.2026.156681_bb0170","article-title":"RPL6 interacts with HMGCS1 to stabilize HIF-1\u03b1 by promoting cholesterol production in hepatocellular carcinoma (in eng)","volume":"12","author":"Yang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"10.1016\/j.metabol.2026.156681_bb0175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic (in eng)","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.metabol.2026.156681_bb0180","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41573-023-00833-z","article-title":"Extracellular targeted protein degradation: an emerging modality for drug discovery (in eng)","volume":"23","author":"Wells","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.metabol.2026.156681_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2024.04.026","article-title":"mTORC1-CTLH E3 ligase regulates the degradation of HMG-CoA synthase 1 through the Pro\/N-degron pathway (in eng)","volume":"84","author":"Yi","year":"2024","journal-title":"Mol Cell"},{"issue":"9","key":"10.1016\/j.metabol.2026.156681_bb0190","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/s41589-024-01618-0","article-title":"A chemical probe to modulate human GID4 Pro\/N-degron interactions (in eng)","volume":"20","author":"Owens","year":"2024","journal-title":"Nat Chem Biol"},{"issue":"37","key":"10.1016\/j.metabol.2026.156681_bb0195","doi-asserted-by":"crossref","first-page":"E3880","DOI":"10.1073\/pnas.1414748111","article-title":"Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging (in eng)","volume":"111","author":"Sapir","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.metabol.2026.156681_bb0200","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1038\/ncomms8229","article-title":"Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure (in eng)","volume":"6","author":"Kho","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156681_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/ueg2.70072","article-title":"The rising global burden of MASLD and other metabolic diseases (2000\u22122021) (in eng)","author":"Danpanichkul","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.metabol.2026.156681_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155958","article-title":"Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 (in eng)","volume":"158","author":"Danpanichkul","year":"2024","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2026.156681_bb0215","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the american heart association (in eng)","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2026.156681_bb0220","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease (in eng)","volume":"111s","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156681_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154233","article-title":"Ursolic acid inhibits the cholesterol biosynthesis and alleviates high fat diet-induced hypercholesterolemia via irreversible inhibition of HMGCS1 in vivo (in eng)","volume":"103","author":"Ma","year":"2022","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.metabol.2026.156681_bb0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-022-00089-w","article-title":"MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db\/db mice via STAT1\/HMGCS1 axis (in eng)","volume":"3","author":"Dong","year":"2022","journal-title":"Mol Biomed"},{"key":"10.1016\/j.metabol.2026.156681_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease? (in eng)","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2026.156681_bb0240","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review (in eng)","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2026.156681_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107539","article-title":"Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response (in eng)","volume":"150","author":"Xiao","year":"2024","journal-title":"Bioorg Chem"},{"issue":"6","key":"10.1016\/j.metabol.2026.156681_bb0250","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00109-024-02440-w","article-title":"Abnormal protein SUMOylation in liver disease: novel target for therapy (in eng)","volume":"102","author":"Yang","year":"2024","journal-title":"J Mol Med (Berl)"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526001927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:59:33Z","timestamp":1787155173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526001927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S0026049526001927"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156681","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SUMOylation of HMGCS1 triggers its ubiquitin-dependent degradation to alleviate hepatic steatosis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156681"}}